| Status ▲ | Population | Trial_Name | Description | Phase | Centers | PI | IIST_Pharma |
| PENDING | Any soft tissue sarcoma undergoing surgery and radiation | Circulating Tumor DNA in Soft Tissue Sarcoma | Liquid biopsy in early disease for soft tissue sarcoma | Proof of Concept | PMH | D. Shultz | IIST |
| RECRUITING | resectable LMS, LPS | SR.7/1809-STBSG/STRASS-2. A Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery versus Surgery Alone for Patients with High Risk Retroperitoneal Sarcoma | Surgery vs. Surgery plus Chemo
| III | PMH
MSH
EORTC | R. Gladdy | NCIC/EORTC |
| RECRUITING | LMS | Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) | ADI-PEG 20 (arginine degrading enzyme) or Placebo Plus Gemcitabine and Docetaxel | III | PMH | A. Razak | Pharma |
| RECRUITING | Chondrosarcoma | A phase 3, multicenter, double blind, randomized, placebo-controlled study of ivosidenib in subjects ≥ 18 years of age with unresectable or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 prior systemic treatment regimen | Ivosidenib vs. placebo | III | PMH | A. Salawu | Pharma |
| RECRUITING | Relapsed/Refractory Solid Tumours | 23ME-00610-CLIN-001 | 23ME-00610 given by intravenous infusion | I/II | SickKids | D. Morgenstern | Pharma |
| RECRUITING | Advanced Solid Tumour/LGG, Age ≥12 years | DAY101-102 | Tovorafenib, Tovorafenib plus pimasertib | 2 | SickKids | D. Morgenstern | Pharma |
| RECRUITING | Recurrent/Refractory Ewing Sarcoma, Hepatoblastoma, Neuroblastoma, Osteosarcoma, Rhabdoid Tumor, Rhabdomyosarcoma, Wilms, Sarcoma | ONITT | Onivyde With Talazoparib or Temozolomide | I | SickKids, BCCH | D. Morgenstern, R. Deyell | IIST |
| RECRUITING | Advanced Solid Tumor | RP-6306 | RP-6306 alone and in combination with RP-3500
| I | SickKids | D. Morgenstern | Pharma |
| RECRUITING | All sarcoma - initial consult | Evaluating the Use of Educational Videos in a Medical Oncology Sarcoma Clinic to Improve Patient Knowledge and Satisfaction | Patient education videos vs SOC | Pilot | MSH and PMH | A. Razak
G. Watson | IIST |
| RECRUITING | All sarcoma | SARQUALITY: Integrating early palliative care in advanced SARcoma patients for enhanced QUALITY of life. | Early intervention palliative care vs SOC | Pilot | MSH and PMH only | A. Razak | IIST |
| RECRUITING | mUPS - first line setting | SRC8: A Randomized Phase III Trial of Doxorubicin + Pembrolizumab versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas | Dox + pembro vs. Dox | III | PMH | A. Salawu | CCTG |
| RECRUITING | Angiogenic sarcomas (EHE, intimal sarcomas, H&N angiosarcomas) | SARC-005: A phase II trial of ABSK043, an oral PD1 inhibitor, in patients with selected sarcomas | ABSK043: 800mg PO BID | II | PMH | A. Razak | IIST |
| RECRUITING | 2nd line GIST | 300383: Phase 3 Study of IDRX-42 (GSK6042981) vs Sunitinib in Participants with Metastatic and/or Unresectable GIST after Imatinib | IDRX-42 vs. sunitinib monotherapy. No crossover. | III | PMH | A. Razak | Pharma |
| RECRUITING | Advanced Sarcoma | Actinium Therapy for Late-stage Aggressive Sarcomas (ATLAS) | safety of drug [Ac225]RTX-2358 and the diagnostic imaging agent [Cu64]LNTH-1363S. Additionally Ratio Therapeutics will learn if [Ac225]RTX-2358 drug is effective in treating advanced sarcoma. | I | PMH | D. Shultz | Pharma |
| CLOSED | Localized high risk sarcoma | Prospective Study of Hypoxia Imaging in Patients with Soft Tissue Sarcoma using Positron Emission Tomography (PET) with 18F-Fluoroazomycin Arabinoside (18F-FAZA) in combination with MRI | FAZA for STS
| Proof of Concept | PMH | D. Shultz | IIST |
| CLOSED | Osteosarcoma | OLIE | ifosfamide and etoposide with or without Lenvatinib in children, adolescents and young adults | I | SickKids | D. Morgenstern | Pharma |
| CLOSED | Relapsed Osteosarcoma (1-35yrs) | PED-CITN-03: Phase 1 Trial of Hu5F9-G4 (Magrolimab) Combined With Dinutuximab in Children and Young Adults With Relapsed and Refractory Neuroblastoma or Relapsed Osteosarcoma | Biological: Dinutuximab, Magrolimab | I | SickKids, BCCH | D. Morgenstern, R. Deyell | NCI |
| CLOSED | Ewing Sarcoma, Rhabdomyosarcoma, Osteosarcoma + other (2 -25yrs) | DCL-17-001: An Open-Label, Dose Escalation, Efficacy, and Safety Study of CLR 131 in Children, Adolescents, and Young Adults With Select Solid Tumors, Lymphoma, and Malignant Brain Tumors | Drug: CLR 131 | I | SickKids | D. Morgenstern | Pharma |
| CLOSED | Ewing Sarcoma, Rhabdomyosarcoma, other Solid Tumors (2-20yrs) | ADVL1921: PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE(REGISTERED)) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE AND/OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS | Palbociclib + chemo | II | SickKids
CHU Ste-Justine | D. Morgernstern
Y. Samson | COG + Pharma |
| CLOSED | High grade soft tissue sarcoma | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients with Select Solid Tumors (FRONTIER) | FAPi radioligand in high grade soft tissue sarcoma | I | PMH | A. Razak | Pharma |
| CLOSED | LMS (fever than 4 lines of prior treatment) | A Phase II/III Study to Evaluate the Efficacy and Safety of Unesbulin in Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma (SUNRISE LMS) | DTIC + unesbulin/placebo | II/III | PMH | A. Salawu | Pharma |
| CLOSED | GIST | (PEAK) A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF CGT9486+SUNITINIB VS SUNITINIB IN SUBJECTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMORS | Sunitinib +/- CGT9486 | III | PMH | A. Razak | Pharma |
| CLOSED | GIST | A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT) | Ripretinib vs sunitinib | III | PMH | A. Razak | Pharma |
| CLOSED | PVNS/TGCT | A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study of ABSK021 to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor (TANGENT) | Emactuzumab vs. placebo | III | PMH | A. Razak | Pharma |
| CLOSED | Relapsed or refractory Solid tumors, lymphoma, brain tumors | BMS BET 19-040 | investigational drug called BMS-986158 | I | SickKids | D. Morgenstern | IIST |
| CLOSED | R/R solid tumor, including CNS tumors, with a mutation in PDGFRA and/or KIT. 2-18 yrs | BLU-285-3101 | This is a Phase 1/2, multicenter, open-label trial of avapritinib, | I/II | SickKids | D. Morgenstern | Pharma |
| CLOSED | Advanced and unresectable or metastatic solid malignancy | BO41932 (TAPISTRY). unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay | Targeted therapies or immunotherapy as single agents or in rational, specified combinations. | II | SickKids | D. Morgenstern | Pharma |
| CLOSED | DDLPS any line | Brightline-4: A Phase III Open-label, Single-arm, Multi-center Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828) Treatment in Patients With Treatment-naïve or Pre-treated Advanced Dedifferentiated Liposarcoma | Brigimadlin (MDM2i) | Drug access trial | PMH | A. Razak | Pharma |
| CLOSED | Osteosarcoma (AYA -residual OST (up to 30 yrs) | CLIN-60000-461: A phase II, randomized, open-label study to assess the efficacy, safety, and pharmacokinetics (PK) of maintenance cabozantinib (XL184) plus best supportive care (BSC) versus BSC in children, adolescents and young adults (AYA) with unresectable residual osteosarcoma either at diagnosis or at first relapse after standard treatment | Cabozantinib + best supportive care vs best supportive care only | II | PMH | A. Gupta | Pharma |
| CLOSED | Metastatic LPS (dedifferentiated, myxoid, round cell and pleomorphic), UPS, or LMS (non-uterine) | INVINCIBLE-3: phase III study for adult subjects with histologically proven, unresectable, locally advanced, inoperable, or metastatic soft tissue sarcomas (IT-03) | Intratumoural injection or SOC trabectedin, eribulin, or pazopanib. | III | PMH | A. Razak | Pharma |
| span class="RECRUITINGgreen">RECRUITING | Children and teens (between 1 month to 17 years old) with Rhabdomyosarcoma (RMS) | MK-9999-01C/LIGHTBEAM-U01 - LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors | HER3-DXd (also known as MK-1022 or patritumab deruxtecan) | I/II | SickKids | D. Morgenstern | Pharma |
| span class="RECRUITINGgreen">RECRUITING | 2 Years to 30 Years with Relapsed/Refractory Ewing Sarcoma | JZP712-101 - A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2D), and Efficacy of Lurbinectedin Monotherapy in Pediatric Participants With Previously Treated Solid Tumors Followed by Expansion to Assess Efficacy and Safety in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma. | Lurbinectedin Monotherapy | I/II | SickKids | D. Morgenstern | Pharma |
| span class="RECRUITINGgreen">RECRUITING | up to 30 Years with recurrent Ewing's Sarcoma, Osteosarcoma, Rhabdomyosarcoma, Liposarcoma | BCC021 - Phase I/II Study of Silmitasertib (CX-4945) in Combination With Chemotherapy in Children and Young Adults With Relapsed Refractory Solid Tumors | Silmitasertib (CX-4945) in Combination With Chemotherapy | I/II | CHU Ste-Justine | M. Marzouki | IIST |
| span class="RECRUITINGgreen">RECRUITING | 6 Months to 25 Years with Ewing Sarcoma | MK-9999-01A/LIGHTBEAM-U01 - LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors | Zilovertamab Vedotin | I/II | Montreal Children's Hospital | C. Vézina | Pharma |